Alkermes : ALKS_ASCO 2022 IR Call Draft_FINAL 6.3.22 815am.p

Nemvaleukin Alfa: A Novel, Engineered Interleukin-2 Variant Immunotherapy


Clinical Data Updates from ARTISTRY-1 Trial


... | June 6, 2022

Related Keywords

, Exchange Commission , Forward Looking Statements , Private Securities Litigation Reform Act , Annual Report , Alkermes Plc Stock Exchange , News , Information , Press Release , Nemvaleukin , Engineered , Variant , Linical , Data , Updates , Rom Alks Ie00b56gvs15 ,